1. Home
  2. |Insights
  3. |What U.S. Government Contractors and Grant Recipients Need To Know About Terminations, Stop Work Orders, Tariffs, and the Path Forward in 2025

What U.S. Government Contractors and Grant Recipients Need To Know About Terminations, Stop Work Orders, Tariffs, and the Path Forward in 2025

Client Alert | 1 min read | 02.07.25

On February 6, 2025, Crowell & Moring presented a webinar, "The New Normal: What U.S. Government Contractors and Grant Recipients Need to Know About Terminations, Stop Work Orders, Tariffs, and the Path Forward in 2025."  In this webinar (available here), Crowell & Moring lawyers specializing in U.S. government contracts and grants addressed:

  • Stop Work Orders
  • De-Scoping Contracts and Grants
  • Partial and Full Terminations for Convenience
  • Non-Payment and Other Breaches
  • The Impact of New Tariffs

Specifically, the discussion focused on potential government actions contractors and grant recipients can expect given recent developments, and the steps that contractors and grant recipients can take now to preserve their rights and protect the bottom line.  This includes responding to and negotiating with government counterparties, providing notice where required, and thinking about cost recovery strategies.

Contacts

Insights

Client Alert | 4 min read | 08.29.25

Gender-Affirming Care Targeted for Potential False Claims Act Enforcement

On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including  Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments....

View All Insights